Key Takeaways
- Demand bottoming, recovery gradual: Management believes the worst is over in H1 FY24, with H2 expected to be consequentially better, but full normalization is still a few quarters away.
- FY24 EBITDA reset to ₹950–1,000 crore: The earlier ₹1,700 crore FY25 ambition now carries a 5–15% downside risk, with FY24 framed as a transitional year of moderated performance.
- Volume recovery is substantially inventory correction: The demand rebound underway is driven more by destocking ending than by a broad-based end-market surge, with agrochemicals remaining the toughest vertical.
- Capex conviction holds despite China headwinds: The ₹2,500–3,000 crore two-year capex plan stays intact, with ethylation, NT expansion and chlorotoluenes projects commissioning in phases from next year.
- What to watch next quarter: Whether the H2 FY24 EBITDA run-rate actually tracks above ₹500 crore, any firm decision on repurposing the first contract plant, and the pace of agrochemical demand stabilization.
Demand Environment
- Recovery is uneven and inventory-led: Discretionary segments like dyes, pigments and polymers are showing QoQ improvement, while agrochemicals remain molecule-specific and challenging. Management confirmed the volume decline was substantially driven by inventory correction, not just underlying demand weakness, and different products are now reaching optimal inventory levels.
- Export momentum stronger than domestic: Direct exports are seeing better traction, with improvement noted in some Asian and European markets. Domestic sales declined 17% sequentially, dragged mainly by agrochemicals where local customers buy intermediates and then export finished goods under downstream pressure.
- Chinese competition tied to global demand: Competitive intensity from China increased in recent quarters as its domestic economy slowed, pushing surplus output into export markets. Management expects this pressure to ease as global demand improves.
- Timeline is measured in quarters, not months: Headwinds are expected to persist over the next few months, with demand revival anticipated over the next two to three quarters. Q3 FY24 typically sees lighter international buying, so more meaningful demand growth is expected in the first half of calendar year 2024.
Rajendra Gogri: "We expect the worst to be over in H1 FY24 and anticipate that it will take a few more quarters for normalised demand across various end segments/product lines. Thus we expect consequentially better performance in H2FY24 and foresee FY25 to be a normalising year considering the current pace of recovery."
Margin Trajectory & Mix Shift
- Per-kg margins have bottomed: Margins in Q1 were the lowest point, with Q2 showing improvement driven by product mix shifting toward higher-margin products and demand stabilization in some traditional, better-margin markets.
- Value-added mix is rising structurally: The percentage of value-added products in the portfolio is increasing overall, which improves the EBITDA margin to sales ratio. Non-regular market margins are generally lower, so the ongoing shift toward more regular markets will accrue future benefit.
- Raw material volatility is largely pass-through: Benzene and other raw material price swings do not materially impact margins: local sales pass through immediately, while export contracts sometimes adjust on a quarterly basis. No significant inventory gains were booked despite a sharp rise in crude derivative prices.
- Operating leverage still ahead: Staff cost optimization has some room left, and operating leverage will kick in as volumes recover across product lines.
Long-Term Contracts: Status & Visibility
- Contract-I plant remains in limbo: The first contract was cancelled and the products continue to suffer on the demand side with no significant improvement. No firm decision has been made on repurposing the plant; management is still evaluating the possibility of using it for the same product and needs a couple more quarters before deciding.
- Contract-II is capacity-utilization-agnostic: This contract is structured such that EBITDA does not depend on how much capacity is utilized, insulating it from volume swings.
- Contract-III is in stabilization mode: The third contract was just commissioned and will contribute no significant EBITDA in FY24. The major gain is expected in FY25, with a gradual ramp-up in H2 FY24 versus H1.
- No blended volume target disclosed: Management declined to provide a blended volume number needed to achieve the earlier ₹1,700 crore EBITDA guidance, citing too many products at different prices.
Capex, Debt & Project Pipeline
- Capex plan unchanged despite macro noise: ₹575 crore was spent in H1 FY24, and the ₹2,500–3,000 crore two-year capex plan remains intact. Management sees no reason to alter it due to Chinese competition, framing the current decade as a golden one for Indian manufacturing given cost competitiveness, talent, domestic market growth and the manufacturing shift away from other Asian and Western countries.
- Ethylation, NT and chlorotoluenes projects on track: These value-chain expansions are progressing and will commission in a phased manner starting next year. Ethylation and nitrotoluene expansions are targeting commissioning toward the end of Q1 FY25, with FY25 seeing progressive volume and EBITDA increases, and the second half better than the first. Good volume visibility exists on the expanded capacities for downstream products.
- Debt peak pushed to FY26: Gross debt stood at ~₹3,200 crore in H1 FY24, with net debt at ~₹2,700–2,800 crore. Net debt is expected to increase in FY25, peak out somewhere in FY26, and then begin tapering off. Management declined to put a specific number on the peak, calling it difficult at this point.
- Acid unit revamp completed: The revamp was finished recently, supporting downstream operations.
Chetan Gandhi: "I believe it should peak-out somewhere in FY26, and from there it will start tapering off. Putting a number at this point of time would be a bit difficult."
Product & End-Market Dynamics
| Segment | Trend | Commentary |
|---|---|---|
| Polymers & Additives | ▲ Growth | Saw volume growth in the quarter. |
| Dyestuff | ▲ Improving | Some recovery visible along with a few specialty applications. |
| Agrochemicals | ▼ Challenging | Molecule-specific demand; the major contributor to the 17% sequential domestic sales decline. |
| Home & Personal Care | ▬ Limited exposure | Some demand pressure but not a material output for the company. |
| Nitro Toluene | ▼ Volume decline | Fell QoQ due to agrochemical demand and some planned shutdowns. No known restriction on Metalochlorine sales in Europe. |
| Octane Booster | ▲ Stable+ | Expected to sustain and possibly grow demand. |
- Export mix expected in 40–55% range: This band is expected to continue, with direct export momentum currently stronger than domestic.
- MPDA anti-dumping duty: Management expects to be able to continue the anti-dumping duty on MPDA.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FY24 EBITDA | ₹950–1,000 crore, with H2 upward of ₹500 crore | FY24 full year |
| FY25 EBITDA vs earlier ₹1,700 crore guidance | At least 5% to 15% decline from ₹1,700 crore, with QoQ increases as demand recovers and new plants commission | FY25 |
| Demand normalization | Demand expected to get normalized; FY25 a normalizing year | H1 calendar year 2024 / FY25 |
| Ethylation & NT expansion commissioning | Targeting end of Q1 FY25; progressive volume and EBITDA increase through FY25, H2 better than H1 | End-Q1 FY25 onward |
| Contract-III contribution | No significant EBITDA in FY24; major gain in FY25 | FY25 |
| Contract-I plant decision | Evaluation continues; decision in a couple more quarters | ~Q4 FY24 / Q1 FY25 |
| Net debt peak | Expected to peak out in FY26, then taper off | FY26 |
| Two-year capex plan | ₹2,500–3,000 crore; no change planned | Through FY25 |
Key Metrics
| Metric | Q2 FY24 |
|---|---|
| Revenue | ₹1,597 cr, up 2% QoQ |
| EBITDA | ₹233 cr, up 16% QoQ |
| Profit after tax | ₹91 cr, up 30% QoQ |
| H1 FY24 EBITDA | ₹433 cr |
| H2 FY24 EBITDA visibility | upward of ₹500 cr |
| FY24 EBITDA guidance | ₹950–1,000 cr |
| FY25 EBITDA guidance | ₹1,450–1,600 cr, 5–15% decline from earlier ₹1,700 cr guidance |
| Nitrochlorobenzene production | 19,014 MT, vs 20,276 MT in Q2 FY23 and 17,293 MT in Q1 FY24 |
| Hydrogenation production | 3,136 TPM, vs 2,558 TPM in Q2 FY23 and 2,868 TPM in Q1 FY24 |
| Nitrotoluene production | 7,560 MT, vs 4,954 MT in Q2 FY23 and 9,320 MT in Q1 FY24 |
| PDA volumes | 316 tons per month |
| H1 FY24 CAPEX | ₹575 cr |
| FY24 target CAPEX | ₹1,200–1,300 cr |
| Two-year CAPEX commitment | ₹2,500–3,000 cr |
| Net debt | ₹2,700–2,800 cr, cash of ₹400+ cr, gross debt ~₹3,200 cr |
| Net debt by end FY24 (worst-case) | ₹2,900 cr |
| Non-regular export markets share | ~10% of total exports |
| Export mix range | 40% to 55% |
| Asset turn for new assets | 1.2x to 1.3x |
| Interest cost revaluation loss | ₹12 cr, on unhedged long-term loans |